Stability and compatibility of antimicrobial lock solutions

American Journal of Health-System Pharmacy

Volumn 70, Issue 24, 2013, Pages 2185-2198

  Bookstaver, P Brandon ^a   Rokas, Kristina E E ^b   Norris, LeAnn B ^a   Edwards, Julie M ^a   Sherertz, Robert J ^c  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b WAKE FOREST BAPTIST HEALTH   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPICILLIN; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CEFAZOLIN; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; DAPTOMYCIN; GENTAMICIN; GLYCYLCYCLINE DERIVATIVE; LINEZOLID; MACROLIDE; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLONE DERIVATIVE; SULFONAMIDE; TELAVANCIN; TETRACYCLINE DERIVATIVE; TIMENTIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN; HEPARIN;

ANTIBIOTIC PROPHYLAXIS; ANTIMICROBIAL LOCK THERAPY; ANTIMICROBIAL THERAPY; CATHETER INFECTION; CATHETER REMOVAL; CENTRAL VENOUS CATHETER; DRUG FORMULATION; DRUG STABILITY; EXCIPIENT COMPATIBILITY; HUMAN; PATIENT SAFETY; PHARMACY; REVIEW; ARTICLE; CENTRAL VENOUS CATHETERIZATION; CHEMISTRY; DRUG INCOMPATIBILITY; METHODOLOGY; TIME;

ANTI-INFECTIVE AGENTS; ANTICOAGULANTS; CATHETER-RELATED INFECTIONS; CATHETERIZATION, CENTRAL VENOUS; DRUG COMPOUNDING; DRUG INCOMPATIBILITY; DRUG STABILITY; HEPARIN; HUMANS; TIME FACTORS;

EID: 84905143436     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp120119     Document Type: Review

References (109)

1. O'Grady NP, Alexander M, Burns LA et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2011; 52(9):e162-93.
2. Carratala J, Niubo J, Fernandez-Sevilla A et al. Randomized, double-blind trial of an antibiotic-lock technique for prevention of gram-positive central venous catheter-related infection in neutropenic patients with cancer. Antimicrob Agents Chemother. 1999; 43:2200-4.
3. Garland JS, Alex CP, Henrickson KJ et al. A vancomycin-heparin lock solution for prevention of nosocomial bloodstream infection in critically ill neonates with peripherally inserted central venous catheters: a prospective, randomized trial. Pediatrics. 2005; 116:e198-205.
4. Kim SH, Song KI, Chang JW et al. Prevention of uncuffed hemodialysis catheter-related bacteremia using an antibiotic lock technique: a prospective, randomized clinical trial. Kidney Int. 2006; 69:161-4.
5. Battistella M, Vercaigne LM, Cote D, Lok CE. Antibiotic lock: in vitro stability of gentamicin and sodium citrate in dialysis catheters at 37 degrees C. Hemodial Int. 2010; 14: 322-6.
6. Battistella M, Walker S, Law S et al. Antibiotic lock: in vitro stability of vancomycin and four percent sodium citrate stored in dialysis catheters at 37 degrees C. Hemodial Int. 2009; 13:322-8.
7. Dotson B, Lynn S, Savakis K et al. Physical compatability of 4% sodium citrate with selected antimicrobial agents. Am J Health-Syst Pharm. 2010; 67:1195-8.
8. Cote D, Lok CE, Battistella M et al. Stability of Trisodium Citrate and Gentamicin Solution for Catheter Locks after Storage in Plastic Syringes at Room Temperature. Can J Hosp Pharm. 2010; 63:304-11.
9. Bookstaver PB, Premnath PN, Edwards JM. Evaluation of compatibility and stability of daptomycin in an antibiotic-anticoagulant lock solution. Presented at: American College of Clinical Pharmacy Annual Meeting, Hollywood, FL, October 21-24, 2012.
10. Shenep LE, Shenep M, Cheatham W et al. Efficacy of intravascular catheter lock solutions containing preservatives in the prevention of microbial colonization. J Hosp Infect. 2011; 79:317-22.
11. Takla TA, Zelenitsky SA, Vercaigne LM. Effectiveness of a 30% ethanol/4% trisodium citrate locking solution in preventing biofilm formation by organisms causing haemodialysis catheterrelated infections. J Antimicrob Chemother. 2008; 62:1024-6
12. Trissel LA. Trissel's 2 clinical pharmaceutics database [electronic database]. Cashiers, NC: TriPharma Communications. Updated regularly.
13. Trissel LA, Flora KP. Stability studies: five years later. Am J Hosp Pharm. 1988; 45:1569-71.
14. Trissel LA. Avoiding common flaws in stability and compatibility studies of injectable drugs. Am J Hosp Pharm. 1983; 40:1159-60.
15. Bookstaver PB, Williamson JC, Tucker BK et al. Activity of novel antibiotic lock solutions in a model against isolates of catheter-related bloodstream infections. Ann Pharmacother. 2009; 43:210-9.
16. Fernandez-Hidalgo N, Almirante B, Calleja R et al. Antibiotic-lock therapy for long-term intravascular catheter-related bacteraemia: results of an open, non-comparative study. J Antimicrob Chemother. 2006; 57:1172-80.
17. Saxena AK, Panhotra BR, Naguib M. Sudden irreversible sensory-neural hearing loss in a patient with diabetes receiving amikacin as an antibiotic-heparin lock. Pharmacotherapy. 2002; 22:105-8.
18. Rao JS, O'Meara A, Harvey T et al. A new approach to the management of Broviac catheter infection. J Hosp Infect. 1992; 22(2):109-16.
19. Sánchez-Muñoz A, Aguado JM, López-Martin A et al. Usefulness of antibiotic-lock technique in management of oncology patients with uncomplicated bacteremia related to tunneled catheters. Eur J Clin Microbiol Infect Dis. 2005; 24(4):291-3.
20. Droste JC, Jeraj H, MacDonald A, Farrington K. Stability and in vitro efficacy of antibiotic-heparin lock solutions potentially useful for treatment of central venous catheter-related sepsis. J Antimicrob Chemother. 2003; 51:849-55.
21. Polgreen PM, Beekmann SE, Diekema DJ et al. Wide variability in the use of antimicrobial lock therapy and prophylaxis among infectious diseases consultants. Infect Control Hosp Epidemiol. 2010; 31(5):554-57.
22. Bailey E, Berry N, Cheesbrough JS. Antimicrobial lock therapy for catheterrelated bacteraemia among patients on maintenance haemodialysis. J Antimicrob Chemother. 2002; 50:615-7.
23. Filiopoulos V, Hadjiyannakos D, Koutis I et al. Approaches to prolong the use of uncuffed hemodialysis catheters: results of a randomized trial. Am J Nephrol. 2011; 33(3):260-8.
24. Vercaigne LM, Siltar DS, Penner SB et al. Antibiotic-heparin lock: in vitro antibiotic stability combined with heparin in a central venous catheter. Pharmacotherapy. 2000; 20(4):394-9.
25. Silva TN, Mendes ML, Abrão JM et al. Successful prevention of tunneled central catheter infection by antibiotic lock therapy using cefazolin and gentamicin. Int Urol Nephrol. 2012 Dec 27. [Epub ahead of print]
26. Moran J, Sun S, Khababa I et al. A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients. Am J Kidney Dis 2011; 59(1):102-107.
27. Chauhan A, Lebeaux D, Ghigo JM et al. Full and broad-spectrum in vivo eradication of catheter-associated biofilms using gentamicin-EDTA antibiotic lock therapy. Antimicrob Agents Chemother. 2012; 56 (12):6310-8.
28. Landry DL, Braden GL, Gobeille SL et al. Emergence of gentamicin-resistant bacteremia in hemodialysis patients receiving gentamicin lock catheter prophylaxis. Clin J Am Soc Nephrol. 2010; 5(10):1799-804.
29. Fernández-Gallego J, Martin M, Gutiérrez E et al. Prophylaxis with gentamicin locking of chronic tunnelled central venous catheters does not cause bacterial resistance. Nefrologia. 2011; 31:308-12.
30. Onder AM, Chandar J, Simon N et al. Comparison of tissue plasminogen activator-antibiotic locks with heparin-antibiotic locks in children with catheter-related bacteraemia. Nephrol Dial Transplant. 2008; 23:2604-10.
31. Onder AM, Chandar J, Billings AA et al. Comparison of early versus late use of antibiotic lock in the treatment of catheter-related bacteremia. Clin J Am Soc Nephrol. 2008; 3(4):1048-56.
32. Onder AM, Chardar J, Billings A et al. Prophylaxis of catheter related bacteremia using tissue plasminogen activator-tobramycin locks. Pediatr Nephrol. 2009; 24(11):2233-43.
33. Anthony TU, Rubin LG. Stability of antibiotics used for antibiotic-lock treatment of infections of implantable venous devices (ports). Antimicrob Agents Chemother. 1999; 43:2074-6.
34. Baker DS, Waldrop B, Arnold J. Compatibility and stability of cefotaxime, vancomycin, and ciprofloxacin in antibiotic lock solutions containing heparin. Int J Pharmaceutical Compound. 2010; 14(4):346-9.
35. Haimi-Cohen Y, Husain N, Meenan J et al. Vancomycin and ceftazidime bioactivities persist for at least 2 weeks in the lumen in ports: simplifying treatment of port-associated bloodstream infections by using the antibiotic lock techniques. Antimicrob Agents Chemother. 2001; 45(5):1565-67.
36. Vercaigne LM, Zelenitsky S, Findlay I et al. An in vitro evaluation of the antibiotic/heparin lock to sterilize central venous haemodialysis catheters. J Antimicrob Chemother. 2002; 49:693-6.
37. Robinson JL, Tawfik G, Saxinger L et al. Stability of heparin and physical compatibility of heparin/antibiotic solutions in concentrations appropriate for antibiotic lock therapy. J Antimicrob Chemother. 2005; 56:951-3.
38. Krishnasami Z, Carlton D, Bimbo L et al. Management of hemodialysis catheter related bacteremia with an adjunctive antibiotic lock solution. Kidney Int. 2002; 61:1136-42.
39. Saxena AK, Panhotra B, Sundaram DS et al. Enhancing the survival of tunneled haemodialysis catheters using an antibiotic lock in the elderly: a randomised, double-blind clinical trial. Nephrology. 2006; 11:299-305.
40. Saxena AK, Panhotra B, Sundaram DS et al. Tunneled catheters' outcome optimization among diabetics on dialysis through antibiotic-lock placement. Kidney Int. 2006; 70:1629-35.
41. Saxena AK, Panhotra BR. The impact of catheter-restricted filling with cefotaxime and heparin on the lifespan of temporary hemodialysis catheters: a case controlled study. J Nephrol. 2005; 18:755-63.
42. Rijnders BJ, Van Wijngaerden E, Vandecasteele SJ, Stas M, Peetermans WE. Treatment of long-term intravascular catheter related bacteraemia with antibiotic lock: randomized, placebo-controlled trial. J Antimicrob Chemother. 2005; 55(1):90-4.
43. Van Praagh AD, Li T, Zhang S et al. Daptomycin antibiotic lock therapy in a rat model of staphylococcal central venous catheter biofilm infections. Antimicrob Agents Chemother. 2011; 55:4081-9.
44. Del Pozo JL, Rodil R, Aguinaga A et al. Daptomycin lock therapy for grampositive long-term catheter-related bloodstream infections. Int J Clin Pract. 2012; 66(3):305-8.
45. Estes R, Theusch J, Beck A et al. Activity of daptomycin with or without 25 percent ethanol compared to combinations of minocycline, EDTA, and 25 percent ethanol against methicillin-resistant Staphylococcus aureus isolates embedded in biofilm. Antimicrob Agents Chemother. 2013; 57(4):1998-2000.
46. Raad I, Hanna H, Jiang Y et al. Comparative activity of daptomycin, linezolid and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother. 2007; 51:1656-60.
47. Capdevilla JA, Galvalda J, Fortea J et al. Lack of antimicrobial activity of sodium heparin for treating experimental catheter-related infection due to Staphylococcus aureus using the antibiotic-lock technique. Clin Microbiol Infect. 2001; 7:206-12.
48. Del Pozo JL, Alonso M, Serrera A, Hernaez S, Aguinaga A, Leiva J. Effectiveness of the antibiotic lock therapy for the treatment of port-related enterococci, Gram-negative, or Gram-positive bacilli bloodstream infections. Diagn Microbiol Infect Dis. 2009; 63:208-12.
49. Ozbek B, Mataraci E. In vitro effectiveness of colistin, tigecycline and levofloxacin alone and combined with clarithromycin and/or heparin as lock solutions against embedded Acinetobacter baumannii strains. J Antimicrob Chemother. 2013; 68:827-30.
50. Passerini de Rossi B, Feldman L, Pineda MS, Vav C, Franco M. Comparative in vitro efficacies of ethanol, EDTA and levofloxacin based catheter lock solutions on eradication of Stenotrophomonas maltophilia biofilms. J Med Microbiol. 2012 May 11. [Epub ahead of print].
51. Santarpia L, Pasanisi F, Alfonsi L et al. Prevention and treatment of implanted central venous catheter (CVC) - related sepsis: a report after six years of home parenteral nutrition. Clin Nutr. 2002; 21(3):207-11.
52. LaPlante KL, Woodmansee S, Mermel LA. Compatibility and stability of telavancin and vancomycin in heparin or sodium citrate lock solutions. Am J Health-Syst Pharm. 2012; 69:1405-9.
53. Bastani B, Amin K, Herr A. Prolonged stability of stored vancomycin, gentamicin, and heparin for use in the antibiotic-lock technique. ASAIO J. 2005; 51:761-3.
54. Soriano A, Bregada E, Marqués JM et al. Decreasing gradient of antibiotic concentration in the lumen of catheters locked with vancomycin. Eur J Clin Microbiol Infect Dis. 2007; 26:659-61.
55. Bastani B, Minton J, Islam S. Insufficient penetration of systemic vancomycin into the PermaCath lumen. Nephrol Dial Transplant. 2000; 15:1035-7.
56. Fortun J, Grill F, Martin-Davila P et al. Treatment of longterm intravascular catheter-related bacteraemia with antibiotic-lock therapy. J Antimicrob Chemother. 2006; 58:816-21.
57. Laplante KL, Mermel LA. In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. Nephrol Dial Transplant. 2007; 22:2239-46.
58. Henrickson KJ, Powell KR, Schwart CL. A dilute solution of vancomycin and heparin retains antibacterial and anticoagulant activities. J Infect Dis. 1988; 157(3):600-1.
59. Yao JD, A.C., Karchmer AW. Vancomycin stability in heparin and total parenteral nutrition solutions: novel approach to therapy of central venous catheter-related infections. JPEN J Parenter Enteral Nutr. 1992; 16(3):268-74.
60. De Sio L, Jenkner A, Milano GM et al. Antibiotic lock with vancomycin and urokinase can successfully treat colonized central venous catheters in pediatric cancer patients. Pediatr Infect Dis J 1004; 23: 963-5.
61. Al-Hwiesh AK. Tunneled catheter-antibiotic lock therapy for prevention of dialysis catheter-related infections: a single center experience. Saudi J Kidney Dis Transpl. 2008; 19:593-602.
62. Dixon JJ, Steele M, Makanjuola AD. Anti-microbial locks increase the incidence of Staphylococcus aureus and antibiotic-resistant Enterobacter: observational retrospective cohort study. Nephrol Dial Transplant. 2012 May 2. [Epub ahead of print].
63. Vincentelli J. Formulation of a flush solution of heparin, vancomycin, and colistin for implantable access systems in oncology. J Oncol Pharm Pract. 1997; 3(1):18-23.
64. Poole CV, Carlton D, Bimbo L et al. Treatment of catheter-related bacteraemia with an antibiotic lock protocol: effect of bacterial pathogen. Nephrol Dial Transplant. 2004; 19(5):1237-44.
65. Qu Y, Istivan TS, Daley AJ et al. Comparison of various antimicrobial agents as catheter lock solutions: preference for ethanol in eradication of coagulase-negative staphylococcal biofilms. J Med Microbiol. 2009; 58(Pt 4):442-50.
66. Information for Healthcare Professionals: Linezolid (marketed as Zyvox). Food and Drug Administration Alert. [cited 2012 February 1]; Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/ucm085249.htm.
67. Wilcox MH, Tack KJ, Bouza E et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis. 2009; 48:203-12.
68. Curtin J, Cormican M, Fleming G et al. Linezolid compared with eperezolid, vancomycin, and gentamicin in an in vitro model of antimicrobial lock therapy for Staphylococcus epidermidis central venous catheter-related biofilm infections. Antimicrob Agents Chemother. 2003; 47:3145-8.
69. Boorgu R, Dubrow AJ, Levin NW et al. Adjunctive antibiotic/anticoagulant lock therapy in the treatment of bacteremia associated with the use of a subcutaneously implanted hemodialysis access device. ASAIO J. 2000; 46(6):767-70.
70. Davanipur M, Pakfetrat M, Roozbeh J. Cloxacillin as an antibiotic lock solution for prevention of catheter-associated infection. Iran J Kidney Dis. 2011; 5(5):328-31.
71. Sherertz RJ, Boger M, Collins CA et al. Comparative in vitro efficacies of various catheter lock solutions. Antimicrob Agents Chemother. 2006; 50:1865-8.
72. Holmberg A, Morgelin M, Rasmussen M. Effectiveness of ciprofloxacin or linezolid in combination with rifampicin against Enterococcus faecalis in biofilms. J Antimicrob Chemother. 2012; 67:433-9.
73. Al Akhrass F, Hachem R, Mohamed JA et al. Central venous catheter-associated Nocardia bacteremia in cancer patients. Emerg Infect Dis. 2011; 17:1651-8.
74. Ghannoum MA, Isham N, Jacobs MR. Antimicrobial activity of B-Lock against bacterial and Candida spp. causing catheter-related bloodstream infections. Antimicrob Agents Chemother. 2011; 55(9):4430-1.
75. Raad I, Hanna H, Dvorak T et al. Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm. Antimicrob Agents Chemother. 2007; 51:78-83.
76. Chatzinikolaou I, Zipf T, Hanna H et al. Minocycline-ethylenediaminetetra-acetate lock solution for the prevention of implantable port infections in children with cancer. Clin Infect Dis. 2003; 36:116-9.
77. Raad I, Hachem R, Tcholakian RK et al. Efficacy of minocycline and EDTA lock solution in preventing catheter-related bacteremia, septic phlebitis, and endocarditis in rabbits. Antimicrob Agents Chemother. 2002; 46:327
78. Bookstaver PB, Sutton SS, Sherertz RJ. Bioactivity of tetracycline antibiotic lock therapy in a model of catheter infection (abstract 475). Presented at Fifth Decennial International Conference on Healthcare-Associated Infections. Atlanta, GA; 2010 March.
79. Miceli MH, Bernardo SM, Lee SA. In vitro analyses of the combination of high-dose doxycycline and antifungal agents against Candida albicans biofilms. Int J Antimicrob Agents. 2009; 34:326-32.
80. Olofsson, A, Hermansson M, Elwing H. N-acetyl-L-cysteine affects growth, extracellular polysaccharide production, and bacterial biofilm formation on solid surfaces. Appl Environ. Microbiol. 2003; 69:4814-22.
81. Ku TS, Palanisamy S, Lee SA. Susceptibility of Candida albicans biofilms to azithromycin, tigecycline and vancomycin and the interaction between tigecycline and antifungals. Int J Antimicrob Agents. 2010; 36:441-6.
82. Bleyer AJ, Mason L, Russell G, Raad II, Sherertz RJ. A randomized, controlled trial of a new vascular catheter flush solution (minocycline-EDTA) in temporary hemodialysis access. Infect Control Hosp Epidemiol 2005; 26: 520-4.
83. Aslam S, Trautner BW, Ramanathan V, Darauiche Ro. Pilot trial of N-acetylcysteine and tigecycline as a catheter lock solution for treatment of hemodialysis catheter-associated bacteremia. Infect Control Hosp Epidemiol 2008; 29: 894-7.
84. Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother. 2004; 48:3407-11.
85. Condie CK, Tyler LS, Barker B, Canann DM. Visual compatibility of caspofungin acetate with commonly used drugs during stimulated Y-site delivery. Am J Health-Syst Pharm. 2008; 65,5:454-57.
86. Bookstaver PB, Harris J, Sides MB, Rudisill CN. Stability and compatibility of candidate antifungal lock solutions of micafungin (abstract 134). Presented at American College of Clinical Pharmacy 2010 Annual Meeting. Austin, Texas; 2010 Oct.
87. Bailey E, Berry N, Cheesbrough JS. Antimicrobial lock therapy for catheter-related bacteraemia among patients on maintenance haemodialysis. J Antimicrob Chemother. 2002; 50:615-7.
88. Raad I, Hachem R, Hanna HA et al. Role of ethylene diamine tetra-acetic acid (EDTA) in catheter lock solutions: EDTA enhances the antifungal activity of amphotericin B lipid complex against Candida embedded in biofilm. Int J Antimicrob Agents. 2008; 32:515-8.
89. Nweze EI, Ghannoum A, Chandra J et al. Development of a 96-well catheter-based microdilution method to test antifungal susceptibility of Candida biofilms. J Antimicrob Chemother. 2012; 67(1):149-53.
90. Uppuluri P, Srinivasan A, Ramasubramanian A et al. Effects of fluconazole, amphotericin B, and caspofungin on Candida albican biofilms under conditions of flow and on biofilm dispersion. Antimicrob Agents Chemother. 2011; 55(7):3591-3.
91. Takla TA, Zelenitsky SA, Vercaigne LM. Effect of ethanol/trisodium citrate lock on microorganisms causing hemodialysis catheter-related infections. J Vasc Access. 2007; 8:262-7.
92. Excelsior Medical. Excelsior Medical's New Catheter Lock Solution. Approved by Health Canada. www.excelsiormedical.com/pdfs/Health-Canada-2010.pdf (accessed 2012 July 7).
93. Rosenblatt J, Reitzel R, Dvorak T et al. Glyceryl Trinitrate Complements Citrate and Ethanol in Eradicating Biofilm Organisms: A Novel Antimicrobial Catheter Lock Solution. Antimicrob Agents Chemother. 2013 May 13. [Epub ahead of print]
94. Chambers ST, Peddle B, Pithie A. Ethanol disinfection of plasticadherent micro-organisms. J Hosp Infect. 2006; 63:193-6.
95. Mouw E, Chessman K, Lesher A et al. Use of an ethanol lock to prevent catheter-related infections in children with short bowel syndrome. J Pediatr Surg. 2008; 43(6):1025-9.
96. Slobbe L, Doorduijn JK, Lugtenburg PJ et al. Prevention of catheter-related bacteremia with a daily ethanol lock in patients with tunnelled catheters: a randomized, placebo-controlled trial. PLoS One. 2010; 5(5):e10840.
97. Filippi L, Pezzati M, Di Amario S et al. Fusidic acid and heparin lock solution for the prevention of catheter-related bloodstream infections in critically ill neonates: a retrospective study and a prospective, randomized trial. Pediatr Crit Care Med. 2007; 8(6):556-62.
98. Al Akhrass F, Al Wohoush I, Chaftari AM et al. Rhodococcus bacteremia in cancer patients is mostly catheter related and associated with biofilm formation. PLoS One. 2012; 7(3):e32945.
99. Sauer K, Steczko J, Ash SR. Effect of a solution containing citrate/Methylene Blue/parabens on Staphylococcus aureus bacteria and biofilm, and comparison with various heparin solutions. J Antimicrob Chemother. 2009; 63(5):937-45.
100. Steczko J, Ash SR, Nivens DE et al. Microbial inactivation properties of a new antimicrobial/antithrombotic catheter lock solution (citrate/methylene blue/parabens). Nephrol Dial Transplant. 2009; 24(6):1937-45.
101. Maki DG, Ash SR, Winger RK et al. A novel antimicrobial and antithrombotic lock solution for hemodialysis catheters: a multi-center, controlled, randomized trial. Crit Care Med. 2011; 39(4):613-20.
102. Filiopoulos V, Hadjiyannakos D, Koutis I et al. Approaches to prolong the use of uncuffed hemodialysis catheters: results of a randomized trial. Am J Nephrol. 2011; 33(3):260-8.
103. Allon M. Prophylaxis against dialysis catheter-related bacteremia with a novel antimicrobial lock solution. Clin Infect Dis. 2003; 36(12):1539-44.
104. Betjes MG, Van Agteren M. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. Nephrol Dial Transplant. 2004; 19(6):1546-51.
105. Simon A, Ammann R, Wiszniewsky G et al. Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients. BMC Infect Dis. 2008; 8:102.
106. Solomon LR, Cheesbrough J, Ebah L et al. A randomized double-blid controlled trial of taurolidine-citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. Am J Kidney Dis. 2010; 55(6):1060-8.
107. Shah CB, Mittelman MW, Costerton JW et al. Antimicrobial activity of a novel catheter lock solution. Antimicrob Agents Chemother. 2002; 46(6):1674-9.
108. Zwiech R, Adelt M, Chrul S. A Taurolidine-Citrate-Heparin Lock Solution Effectively Eradicates Pathogens From the Catheter Biofilm in Hemodialysis Patients. Am J Ther. 2013 May 9. [Epub ahead of print]
109. TauroLock™. Available at: http://www.taurolock.com (accessed 2013 Apr 1).